A BILL 
To amend the Internal Revenue Code of 1986 to restore 
the amount of the orphan drug tax credit, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as ‘‘Cameron’s Law’’. 
4
03:45 Jun 02, 2021
H2623
2 
•HR 2623 IH
SEC. 2. RESTORATION OF AMOUNT OF ORPHAN DRUG TAX 
1
CREDIT. 
2
(a) IN GENERAL.—Section 45C(a) of the Internal 
3
Revenue Code of 1986 is amended by striking ‘‘25 per-
4
cent’’ and inserting ‘‘50 percent’’. 
5
(b) EFFECTIVE DATE.—The amendment made by 
6
this section shall apply to taxable years beginning after 
7
the date of the enactment of this Act. 
8
SEC. 3. CDC FEASIBILITY STUDY ON SURVEILLANCE INFRA-
9
STRUCTURE FOR RARE DISEASES AND CON-
10
DITIONS. 
11
(a) STUDY.—Not later than 1 year after the date of 
12
enactment of this Act, the Director of the Centers for Dis-
13
ease Control and Prevention (in this section referred to 
14
as the ‘‘Director’’) shall complete a study to evaluate the 
15
feasibility of enhancing and expanding the infrastructure 
16
to track the epidemiology of rare diseases and conditions, 
17
including with respect to the following: 
18
(1) Rates of mortality. 
19
(2) Potential for research and treatment. 
20
(3) Demographics. 
21
(4) Diagnosis and progression markers. 
22
(5) The history of the disease or condition. 
23
(6) Detection management. 
24
03:45 Jun 02, 2021
H2623
3 
•HR 2623 IH
(b) CONSULTATION.—In conducting the study re-
1
quired by subsection (a), the Director shall consult with 
2
relevant experts, including— 
3
(1) epidemiologists with experience in disease 
4
surveillance; 
5
(2) representatives of national voluntary health 
6
associations; 
7
(3) health information technology experts or 
8
other information management specialists; 
9
(4) clinicians with expertise in rare diseases or 
10
conditions; 
11
(5) research scientists with expertise in rare 
12
diseases or conditions, or experience conducting 
13
translational research or utilizing surveillance sys-
14
tems for scientific research purposes; and 
15
(6) patients, and caregivers of patients, with 
16
rare diseases or conditions. 
17
(c) REPORT.—Not later than 3 months after com-
18
pleting the study required by subsection (a), the Director 
19
shall submit a report to the Congress on the results of 
20
the study. 
21
(d) DEFINITION.—In this section, the terms ‘‘rare 
22
diseases and conditions’’ and ‘‘rare diseases or conditions’’ 
23
refer to human diseases and conditions that are— 
24
03:45 Jun 02, 2021
H2623
4 
•HR 2623 IH
(1) a rare disease or condition, as defined in 
1
section 526 of the Federal Food, Drug, and Cos-
2
metic Act (21 U.S.C. 360bb); or 
3
(2) determined by the Director to be rare and 
4
lacking in treatment options, so as to warrant con-
5
sideration in the study required by subsection (a). 
6
Æ 
03:45 Jun 02, 2021
H2623
